Literature DB >> 23086111

The economic burden of inflammatory bowel disease: clear problem, unclear solution.

Christian D Stone.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23086111     DOI： 10.1007/s10620-012-2417-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  10 in total

1.  Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.

Authors:  Gary R Lichtenstein; Songkai Yan; Mohan Bala; Marion Blank; Bruce E Sands
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

Review 2.  The pharmacoeconomics of biologic therapy for IBD.

Authors:  Russell D Cohen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

Review 3.  Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review.

Authors:  K T Park; Dorsey Bass
Journal:  Inflamm Bowel Dis       Date:  2010-11-04       Impact factor: 5.325

4.  The burden of selected digestive diseases in the United States.

Authors:  Robert S Sandler; James E Everhart; Mark Donowitz; Elizabeth Adams; Kelly Cronin; Clifford Goodman; Eric Gemmen; Shefali Shah; Aida Avdic; Robert Rubin
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

5.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Carol Q Porter; Daniel A Ollendorf; Robert S Sandler; Joseph A Galanko; Jonathan A Finkelstein
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

6.  Resource use in patients with Crohn's disease treated with infliximab.

Authors:  C Saro; C da la Coba; M A Casado; J M Morales; B Otero
Journal:  Aliment Pharmacol Ther       Date:  2007-09-07       Impact factor: 8.171

7.  Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.

Authors:  Brian G Feagan; Remo Panaccione; William J Sandborn; Geert R D'Haens; Stefan Schreiber; Paul J Rutgeerts; Edward V Loftus; Kathleen G Lomax; Andrew P Yu; Eric Q Wu; Jingdong Chao; Parvez Mulani
Journal:  Gastroenterology       Date:  2008-08-03       Impact factor: 22.682

Review 8.  How expensive is inflammatory bowel disease? A critical analysis.

Authors:  Selwyn Odes
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

9.  The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Ken Kleinman; Dan Ollendorf; Athos Bousvaros; Richard J Grand; Jonathan A Finkelstein
Journal:  Clin Gastroenterol Hepatol       Date:  2007-09-29       Impact factor: 11.382

10.  Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey.

Authors:  Candace Gunnarsson; Jie Chen; John A Rizzo; Joseph A Ladapo; Jennifer H Lofland
Journal:  Dig Dis Sci       Date:  2012-07-12       Impact factor: 3.199
  10 in total
  20 in total

1.  Genetic association between CARD9 variants and inflammatory bowel disease was not replicated in a Chinese Han population.

Authors:  Zhengting Wang; Rong Fan; Lei Wang; Jie Zhou; Sichang Zheng; Shurong Hu; Mengmeng Chen; Tianyu Zhang; Yun Lin; Maochen Zhang; Jie Zhong
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 2.  Associations between CD24 gene polymorphisms and inflammatory bowel disease: A meta-analysis.

Authors:  Xiao-Li Huang; Dong-Hua Xu; Guo-Pin Wang; Shu Zhang; Cheng-Gong Yu
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

Review 3.  IBD and the gut microbiota--from bench to personalized medicine.

Authors:  Emanuelle Bellaguarda; Eugene B Chang
Journal:  Curr Gastroenterol Rep       Date:  2015-04

Review 4.  Domino effect of hypomagnesemia on the innate immunity of Crohn's disease patients.

Authors:  Saleh A Naser; Almatmed Abdelsalam; Saisathya Thanigachalam; Abed S Naser; Karel Alcedo
Journal:  World J Diabetes       Date:  2014-08-15

5.  Clinical characterization of in vivo inflammatory bowel disease with Raman spectroscopy.

Authors:  Isaac J Pence; Dawn B Beaulieu; Sara N Horst; Xiaohong Bi; Alan J Herline; David A Schwartz; Anita Mahadevan-Jansen
Journal:  Biomed Opt Express       Date:  2017-01-04       Impact factor: 3.732

6.  JAK2 rs10758669 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis.

Authors:  Ji-Xiang Zhang; Jia Song; Jun Wang; Wei-Guo Dong
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

7.  miR-200b-3p alleviates TNF-α-induced apoptosis and inflammation of intestinal epithelial cells and ulcerative colitis progression in rats via negatively regulating KHDRBS1.

Authors:  Chunju Zheng; Ting Lu; Zhimin Fan
Journal:  Cytotechnology       Date:  2021-09-11       Impact factor: 2.040

8.  Appropriateness of emergency department use in pediatric inflammatory bowel disease: a quality improvement opportunity.

Authors:  Edward J Hoffenberg; K T Park; Dana M Dykes; Jacqueline Fridge; Michael D Kappelman; Ian H Leibowitz; V Marc Tsou; Richard B Colletti
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-09       Impact factor: 2.839

9.  Drug Lag for Inflammatory Bowel Disease Treatments in the East and West.

Authors:  Shinji Okabayashi; Taku Kobayashi; Toshifumi Hibi
Journal:  Inflamm Intest Dis       Date:  2018-10-05

10.  The -173 G/C polymorphism of the MIF gene and inflammatory bowel disease risk: a meta-analysis.

Authors:  Yongchun Shen; Shujin Guo; Ting Yang; Liuqun Jia; Lei Chen; Jing An; Tao Wang; Fuqiang Wen
Journal:  Int J Mol Sci       Date:  2013-05-28       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.